ANAB
AnaptysBio, Inc.
15.01
USD
This page is just a preview of the data found in TrendSpider’s full version
AnaptysBio, Inc. stock is down -14.38% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 71.43% of the previous 6 December’s closed higher than November.
AnaptysBio, Inc. engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
